New study of Pfizer’s Nivestim® against Neupogen®

Jan 3, 2020

New study demonstrates noninferiority of Pfizer’s Nivestim® to reference Neupogen®. Additionally, the study demonstrated that those in the biosimilar group reported a shorter median hospitalisation period by two days.

Print Page Mail Article